Amgen And Allergan Receive Positive Opinion For Biosimilar

Amgen And Allergan receive positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ABP 980 (Biosimilar Herceptin) for the treatment of three types of cancer.